Adult ID

Epi/Infection Control

Oral Abstract

227 - Novel Antimicrobials and Approaches Against MDR Organisms

Presentations:

• 10:30 AM - 10:45 AM

  1951 - Extended Infusions of Beta-lactam Antibiotics are Feasible and May Improve Mortality in the Pediatric Population
  Rachael L. Schortemeyer, PharmD – Children's Hospital of Wisconsin; Tracy N. Zembles, PharmD – Children's Hospital of Wisconsin; Glenn .. Bushee, MS – Children's Hospital of Wisconsin; Evelyn .. Kuhn, PhD – Children's Hospital of Wisconsin; Michelle L. Mitchell, MD – Medical College of Wisconsin
• 10:45 AM - 11:00 AM

  1952 - Bacteriophage Treatment Improves Survival of Mice Infected with Carbapenem-Resistant Klebsiella pneumoniae
  Shayla Hesse, MD – National Cancer Institute; Natalia Malachowa, PhD – National Institute of Allergy and Infectious Diseases; Adeline Porter, BS – National Institute of Allergy and Infectious Diseases; Brett Freedman, BS – National Institute of Allergy and Infectious Diseases; Scott Kobayashi, PhD – National Institute of Allergy and Infectious Diseases; Sankar Adhya, PhD – National Cancer Institute; Frank DeLeo, PhD – National Institute of Allergy and Infectious Diseases
• 11:00 AM - 11:15 AM

  1953 - VE303, a Rationally Designed Bacterial Consortium for Prevention of Recurrent Clostridioides difficile (C. Difficile) infection (rCDI), Stably Restores the Gut Microbiota after Vancomycin (Vanco)-Induced Dysbiosis in Adult Healthy Volunteers (HV)
  Dmitri Bobilev, MD – Vedanta Biosciences; Shakti Bhattarai, MS – University of Massachusetts; Rajita Menon, PhD – Vedanta BIosciences; Brian Klein, PhD – Vedanta Biosciences; Shilpa Reddy, MS – Vedanta Biosciences; Bernat Olle, PhD – Vedanta Biosciences; Bruce Roberts, PhD – Vedanta Biosciences; Vanni Bucci, PhD – University of Massachusetts; Jason Norman, PhD – Vedanta Biosciences
• 11:15 AM - 11:30 AM

  1954 - In Vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida Auris Invasive Candidiasis
  Nathan P. Wiederhold, PharmD – University of Texas Health San Antonio; Laura K. Najvar, BS – University of Texas Health San Antonio; Karen J. Shaw, PhD – Amplyx Pharmaceuticals; Rosie Jaramillo – University of Texas Health San Antonio; Hoja P. Patterson, BS – University of Texas Health San Antonio; Marcos Olivo – University of Texas Health San Antonio; Gabriel Catano, MD – University of Texas Health San Antonio; Thomas F. Patterson, MD – University of Texas Health San Antonio
• 11:30 AM - 11:45 AM

  1955 - Novel Compound Reverses Vancomycin Resistance in Vancomycin Resistant Enterococci (VRE)
  Kenneth Onyedibe, MBBS, MSc, FWACP, FMCPath – Purdue Institute for Immunology, Inflammation & Infectious Diseases, Purdue University; Neetu Dayal, PhD – Purdue Institute for Drug Discovery, Purdue University; Herman Sintim, PhD – Purdue Institute for Drug Discovery, Purdue University

Co-Author(s)

• RS

  Rachael Schortemeyer, PharmD

  Pharmacist
  Children's Hospital of Wisconsin
  Milwaukee, WI

  Disclosure: Nothing to disclose
• SB

  Shakti Bhattarai, MS

  PhD candidate
  University of Massachusetts
  N.Dartmouth, Massachusetts

  Disclosure: Nothing to disclose
• ND

  Neetu Dayal, PhD

  Postdoctoral Research Associate
  Purdue Institute for Drug Discovery, Purdue University
  West Lafayette, IN

  Disclosure: Nothing to disclose
• NM

  Natalia Malachowa, PhD

  Staff Scientist
  National Institute of Allergy and Infectious Diseases
  Hamilton, MT

  Disclosure: Nothing to disclose
• LN

  Laura Najvar, BS

  Laboratory Supervisor
  University of Texas Health San Antonio
  San Antonio, TX

  Disclosure: Nothing to disclose
• GB

  Glenn Bushee, MS

  Data analyst
  Children's Hospital of Wisconsin
  Wauwatosa, WI

  Disclosure: Nothing to disclose
• RM

  Rajita Menon, PhD

  Scientist
  Vedanta BIosciences
  Cambridge, MA

  Disclosure: Vedanta Biosciences: Employee
• AP

  Adeline Porter, BS

  Microbiologist
  National Institute of Allergy and Infectious Diseases
  Hamilton, MT

  Disclosure: Nothing to disclose
• KS

  Karen Shaw, PhD

  CSO
  Amplyx Pharmaceuticals
  San Diego, California

  Disclosure: Amplyx Pharmaceuticals: Employee
• HS

  Herman Sintim, PhD

  Drug Discovery Professor
  Purdue Institute for Drug Discovery, Purdue University
  West Lafayette, IN

  Disclosure: Nothing to disclose
• BF

  Brett Freedman, BS

  Microbiologist
  National Institute of Allergy and Infectious Diseases
  Hamilton, MT

  Disclosure: Nothing to disclose
• RJ

  Rosie Jaramillo

  Research Assistant
  University of Texas Health San Antonio
  San Antonio, TX

  Disclosure: Nothing to disclose
• BK

  Brian Klein, PhD

  Scientist
  Vedanta Biosciences
  Cambridge, MA

  Disclosure: Vedanta Biosciences: Employee
• EK

  Evelyn Kuhn, PhD

  Sr Statistical Analyst
  Children's Hospital of Wisconsin
  Wauwatosa, WI

  Disclosure: Nothing to disclose
• SK

  Scott Kobayashi, PhD

  Staff Scientist
  National Institute of Allergy and Infectious Diseases
  Hamilton, MT

  Disclosure: Nothing to disclose
• MM

  Michelle Mitchell, MD

  Assistant Professor of Pediatrics
  Medical College of Wisconsin
  Elm Grove, Wisconsin

  Disclosure: Nothing to disclose
• HP

  Hoja P. Patterson, BS

  Chief Medical Technologist
  University of Texas Health San Antonio
  San Antonio, TX

  Disclosure: Nothing to disclose
• SR

  Shilpa Reddy, MS

  Principal Research Associate
  Vedanta Biosciences
  Cambridge, MA

  Disclosure: Vedanta Biosciences: Employee
• SA

  Sankar Adhya, PhD

  Senior Investigator
  National Cancer Institute
  Bethesda, MD

  Disclosure: Nothing to disclose
• MO

  Marcos Olivo

  Research Assistant
  University of Texas Health San Antonio
  San Antonio, TX

  Disclosure: Nothing to disclose
• BO

  Bernat Olle, PhD

  CEO
  Vedanta Biosciences
  Cambridge, MA

  Disclosure: Vedanta Biosciences: Employee
• GC

  Gabriel Catano, MD

  Research Scientist
  University of Texas Health San Antonio
  San Antonio, TX

  Disclosure: Nothing to disclose
• FD

  Frank DeLeo, PhD

  Senior Investigator and Lab Chief
  National Institute of Allergy and Infectious Diseases
  Hamilton, MT

  Disclosure: Nothing to disclose
• BR

  Bruce Roberts, PhD

  CSO
  Vedanta Biosciences
  Cambridge, MA

  Disclosure: Vedanta Biosciences: Employee
• VB

  Vanni Bucci, PhD

  Assistant Professor
  University of Massachusetts
  N.Dartmouth, Massachusetts

  Disclosure: Nothing to disclose
• TP

  Thomas Patterson, MD

  Professor
  University of Texas Health San Antonio
  San Antonio, TX

  Disclosure: Astellas: Consultant
  Basilea: Consultant
  Cidara: Grant/Research Support
  Gilead: Consultant
  Merck: Consultant
  Pfizer: Consultant
  Scynexis: Consultant
  Toyama: Consultant
  Viamet: Consultant
• JN

  Jason Norman, PhD

  Associate Director
  Vedanta Biosciences
  Cambridge, MA

  Disclosure: Vedanta Biosciences: Employee

Moderator(s)

• 

  William Miller, MD

  Assistant Professor
  Center for Antimicrobial Resistance and Microbial Genomics, UTHealth
  Houston, Texas

  Disclosure: Entasis: Grant/Research Support
  Merck: Grant/Research Support
  Shionogi: Advisory Board
• 

  Jose Munita, MD

  Associate Professor
  Genomics and Resistant Microbes (GeRM) Group. Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R)
  Santiago, Region Metropolitana, Chile

  Disclosure: Biomerieux: Grant/Research Support
  Merck, Sharpe, and Dohme: Grant/Research Support
  Pfizer: Grant/Research Support

Presenting Author(s)

• DB

  Dmitri Bobilev, MD

  VP, Clinical Development
  Vedanta Biosciences
  Cambridge, MA

  Disclosure: Vedanta Biosciences : Employee
• SH

  Shayla Hesse, MD

  ID fellow
  National Cancer Institute
  Rockville, MD

  Disclosure: Nothing to disclose
• KO

  Kenneth Onyedibe, MBBS, MSc, FWACP, FMCPath

  Graduate Research Fellow
  Purdue Institute for Immunology, Inflammation & Infectious Diseases, Purdue University
  West Lafayette, IN

  Disclosure: Nothing to disclose
• NW

  Nathan Wiederhold, PharmD

  Professor
  University of Texas Health San Antonio
  San Antonio, TX

  Disclosure: Astellas: Grant/Research Support
  bioMerieux: Grant/Research Support
  Cidara: Grant/Research Support
  F2G: Grant/Research Support
  Gilead: Speaker's Bureau
  Mayne Pharmaceuticals: Advisor or Review Panel member
  Viamet: Grant/Research Support
• TZ

  Tracy Zembles, PharmD

  Pharmacist
  Children's Hospital of Wisconsin
  Menomonee Falls, WI

  Disclosure: Nothing to disclose